Global pharmaceutical major Lupin has received approval from the US Food and Drug Administration (FDA) for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar referencing Lucentis, marking a significant milestone in the company’s expanding biosimilars portfolio. The approval makes Ranluspec the only interchangeable ranibizumab biosimilar in the United States available in both vial and pre-filled syringe (PFS) presentations. […]